Epithelial Cell Adhesion Molecule (EpCAM)

Overview

Epithelial cell adhesion molecule (EpCAM), also known as CD326, is a cell-surface glycoprotein widely used as a marker of epithelial-derived cells and many epithelial tumors. In biomedical research, EpCAM is most often discussed as a tumor-associated target rather than as a classical adhesion receptor, because its expression is frequently increased in carcinomas and can be exploited for tumor detection, imaging, biomarker enrichment, and targeted therapy.

Biologically, EpCAM is relevant to cancer cell behavior, including tumor cell identification and the study of stemness-associated phenotypes. In recent research, EpCAM has been linked with epithelial tumors such as colorectal cancer, head and neck squamous cell carcinoma, and other EpCAM-positive malignancies. Its presence on tumor cells and tumor-derived extracellular vesicles has made it a useful target for liquid biopsy approaches, fluorescence-guided delineation, and engineered immunotherapies, including bispecific antibodies and CAR-T cells.

Recent Publications Summary

Recent studies have positioned EpCAM as a versatile cancer biomarker and therapeutic target across multiple epithelial malignancies. EpCAM is substantially overexpressed in hepatocellular carcinoma, head and neck squamous cell carcinoma, and pancreatic tumors 42178533May42117374May, and is selectively enriched on the surface of tumor-derived extracellular vesicles, enabling its use for non-invasive cancer diagnostics 42117374May42011810Apr41719909Feb.

Immunotherapeutic strategies have increasingly leveraged EpCAM for targeted cancer treatment. A bispecific antibody (KK2269) designed to simultaneously target EpCAM on tumor cells and CD40 on antigen-presenting cells demonstrated significant antitumor efficacy when combined with chemotherapy, particularly docetaxel, in immunologically cold tumor models 41989931Apr. CAR-T cell therapies engineered with EpCAM-targeting single-chain variable fragments have been optimized for solid tumors including liver malignancies, with structural refinements—such as electrostatic charge optimization—designed to reduce T-cell exhaustion and improve therapeutic efficacy 42538870Aug.

EpCAM-based diagnostic innovations have advanced both intraoperative surgical guidance and liquid biopsy applications. Near-infrared fluorescent antibodies targeting EpCAM enable real-time, microscopic delineation of tumor margins during surgical resection of head and neck squamous cell carcinoma 42178533May. In liquid biopsy, EpCAM serves as a selective capture target for tumor-derived extracellular vesicles; molecularly imprinted polymers and plasmonic microfluidic assays isolate EpCAM-positive EVs from plasma and urine for proteomic profiling and early cancer detection 42117374May42011810Apr41719909Feb. EpCAM expression levels on exosomes vary significantly across cancer types, with breast cancer-derived exosomes showing substantially higher EpCAM than lung and cervical cancer exosomes 41719909Feb.

EpCAM also serves as a marker of cancer stem cell properties in hepatocellular carcinoma; its expression is regulated by oncogenic signaling pathways including the PI3K/Akt axis, and its downregulation correlates with reduced tumorigenicity, suggesting a mechanistic link to therapy resistance and disease recurrence 41651174Feb.

What Changes, What Holds

1. EpCAM is now supported as a broader cross-cancer biomarker and extracellular vesicle target
NEW DIRECTION Recent work extends EpCAM beyond the epithelial-tumor marker role already in the Overview by strengthening its use across hepatocellular carcinoma, head and neck squamous cell carcinoma, and pancreatic tumors, and by emphasizing selective enrichment on tumor-derived extracellular vesicles for non-invasive diagnostics 42178533May42117374May. That does not displace the baseline account, but it widens the practical scope of EpCAM-based detection and liquid biopsy.

2. EpCAM-targeted immunotherapy is being pushed toward combination and engineering strategies
REINFORCES The new studies do not change what EpCAM is understood to be; they sharpen the therapeutic direction already described in the Overview by showing that EpCAM-directed bispecific and CAR-T approaches can be optimized for solid tumors and may work better with chemotherapy, especially docetaxel 41989931Apr42538870Aug. The main implication is not a new role for EpCAM, but that its value as a target may depend on pairing with immune activation or structural tuning to overcome solid-tumor resistance.

3. EpCAM-guided imaging and liquid biopsy are becoming more operationally specific
REINFORCES Near-infrared antibody guidance for surgical margin visualization and EpCAM-positive extracellular vesicle capture both fit squarely within the Overview’s existing themes of imaging and biomarker enrichment 42178533May42011810Apr41719909Feb. What changes is the level of technical maturity: EpCAM is moving from a general marker to a more actionable handle for intraoperative delineation and plasma or urine EV profiling. The breast-cancer exosome comparison further supports heterogeneity in how much signal EpCAM can provide across tumors.

4. EpCAM’s stemness association in hepatocellular carcinoma is strengthened, but the mechanism remains context-dependent
REINFORCES The new hepatocellular carcinoma data align with the Overview’s statement that EpCAM is relevant to stemness-associated phenotypes and tumor behavior, while adding a more explicit mechanistic link to PI3K/Akt signaling and reduced tumorigenicity when EpCAM is downregulated 41651174Feb. That reinforces EpCAM as more than a passive marker in this setting, but it does not overturn the baseline; instead, it suggests a pathway-level explanation for recurrence and therapy resistance that still needs broader validation.

Overview update candidates: broader biomarker use across additional epithelial malignancies; EV-based diagnostic targeting; combination immunotherapy and CAR-T engineering refinements; intraoperative fluorescence guidance; EV capture for liquid biopsy; PI3K/Akt-linked regulation of EpCAM in hepatocellular carcinoma; association with tumorigenicity and recurrence.